French dupilumab EAP in toddlers: Durable response or follow‐up bias?

Key Points

• The aim is to evaluate the response to dupilumab treatment in toddlers and the potential for bias in follow-up results.
• Analysis of previously published articles concerning dupilumab
• Evaluation of data regarding treatment outcomes in toddlers
• Discussion of biases in follow-up data
• No new patient-level data was presented in this letter
• Insights were drawn from existing literature on dupilumab's effectiveness
• Concerns were raised about potential follow-up biases affecting reported outcomes